{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:15:27Z","timestamp":1740147327963,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T00:00:00Z","timestamp":1703376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T00:00:00Z","timestamp":1703376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska Institutet Research Fond"},{"name":"Nanjing 345 overseas high-level talent program"},{"name":"General Program of Medical Research Project of Jiangsu Health and Family Planning Commission"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The treatment resistance is a problem for lung cancer. In this study, we used a vitro tissue culturing system to select a new therapy strategy for a patient with tyrosine kinase inhibitors (TKIs) resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 42-year-old male Asian patient was diagnosed with advanced lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) gene. The patient was treated with Gefitinib, resulting in an almost complete remission for over a year. The patient relapsed after 13\u00a0months treatment, and received four cycles of chemotherapy. At 20\u00a0months, the patient had developed multiple lung metastases and a solitary cerebellar metastasis. An EGFR T790M mutation was identified in the peripheral blood sample. Subsequent treatment with Osimertinib resulted in a complete response of the intracranial metastasis. By 33\u00a0months, the patient had developed a mediastinal tumor mass that responded well to local radiotherapy. By 39\u00a0months, an EGFR C797S cis-mutation had been identified and the patient was treated with Brigatinib and Cetuximab. By 44\u00a0months, the tumor cells from the pleural effusion had been tested for sensitivity against 30 targeted and cytostatic drugs using the D\u2009~\u2009Sense ex-vivo viability assay. The assay identified 8 drugs with moderate to high sensitivity. Combination therapy of Gemcitabin and Lobaplatin had resulted in disease stabilization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The case showed that individualized treatment aided by D\u2009~\u2009Sense ex-vivo viability assay can be a viable option for patients with advanced lung adenocarcinoma with pleural effusions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04277-2","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T01:02:05Z","timestamp":1703379725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The D\u2009~\u2009Sense ex-vivo viability assay application in a patient with stage IV lung adenocarcinoma: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matyas","family":"Bendek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"\u00d6tv\u00f6s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6144-6573","authenticated-orcid":false,"given":"Laszlo","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,24]]},"reference":[{"key":"4277_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/CCO.0000000000000429","volume":"30","author":"F Oberndorfer","year":"2018","unstructured":"Oberndorfer F, Mullauer L. Molecular pathology of lung cancer: current status and perspectives. Curr Opin Oncol. 2018;30:69\u201376. https:\/\/doi.org\/10.1097\/CCO.0000000000000429.","journal-title":"Curr Opin Oncol"},{"key":"4277_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/cco.0000000000000495","volume":"31","author":"J Roeper","year":"2019","unstructured":"Roeper J, Griesinger F. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy? Curr Opin Oncol. 2019;31:1\u20137. https:\/\/doi.org\/10.1097\/cco.0000000000000495.","journal-title":"Curr Opin Oncol"},{"key":"4277_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19:39\u201356. https:\/\/doi.org\/10.1038\/s41573-019-0044-1.","journal-title":"Nat Rev Drug Discov"},{"key":"4277_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/CCO.0000000000000592","volume":"32","author":"R Pirker","year":"2020","unstructured":"Pirker R. Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. Curr Opin Oncol. 2020;32:63\u20137. https:\/\/doi.org\/10.1097\/CCO.0000000000000592.","journal-title":"Curr Opin Oncol"},{"key":"4277_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.7150\/ijms.34739","volume":"16","author":"F Zito Marino","year":"2019","unstructured":"Zito Marino F, Bianco R, Accardo M, et al. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. Int J Med Sci. 2019;16:981\u20139. https:\/\/doi.org\/10.7150\/ijms.34739.","journal-title":"Int J Med Sci"},{"key":"4277_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-76478-8","volume-title":"Serous effusions: etiology, diagnosis, prognosis and therapy","author":"B Davidson","year":"2018","unstructured":"Davidson B, Firat P, Michael CW. Serous effusions: etiology, diagnosis, prognosis and therapy. Berlin: Springer; 2018."},{"key":"4277_CR7","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/0008-5472.CAN-16-1121","volume":"77","author":"E Karekla","year":"2017","unstructured":"Karekla E, Liao WJ, Sharp B, et al. Ex-vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Cancer Res. 2017;77:2029\u201339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1121.","journal-title":"Cancer Res"},{"key":"4277_CR8","doi-asserted-by":"publisher","first-page":"e000536","DOI":"10.1136\/esmoopen-2019-000536","volume":"4","author":"R Di Liello","year":"2019","unstructured":"Di Liello R, Ciaramella V, Barra G, et al. Ex-vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. ESMO Open. 2019;4:e000536. https:\/\/doi.org\/10.1136\/esmoopen-2019-000536.","journal-title":"ESMO Open"},{"key":"4277_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.18632\/genesandcancer.56","volume":"6","author":"R Otvos","year":"2015","unstructured":"Otvos R, Szulkin A, Hillerdal CO, et al. Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma. Genes Cancer. 2015;6:119\u201328. https:\/\/doi.org\/10.18632\/genesandcancer.56.","journal-title":"Genes Cancer"},{"issue":"709","key":"4277_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2407-14-709","volume":"14","author":"A Szulkin","year":"2014","unstructured":"Szulkin A, Otvos R, Hillerdal CO, et al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. BMC Cancer. 2014;14(709):6. https:\/\/doi.org\/10.1186\/1471-2407-14-709.","journal-title":"BMC Cancer"},{"key":"4277_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1001\/jamaoncol.2015.3113","volume":"1","author":"H West","year":"2015","unstructured":"West H, Jin JO. Performance status in patients with cancer. JAMA Oncol. 2015;1:998\u2013998. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3113.","journal-title":"JAMA Oncol"},{"key":"4277_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/jco.2011.39.4486","volume":"30","author":"DB Costa","year":"2012","unstructured":"Costa DB. More than just an oncogene translocation and a kinase inhibitor: Kevin\u2019s story. J Clin Oncol. 2012;30:110\u20132. https:\/\/doi.org\/10.1200\/jco.2011.39.4486.","journal-title":"J Clin Oncol"},{"key":"4277_CR13","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim M, Mun H, Sung CO, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10:3991. https:\/\/doi.org\/10.1038\/s41467-019-11867-6.","journal-title":"Nat Commun"},{"key":"4277_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.exphem.2015.08.009","volume":"44","author":"SE Sylvan","year":"2016","unstructured":"Sylvan SE, Skribek H, Norin S, et al. Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: an in vitro comparative study. Exp Hematol. 2016;44:38-49.e31. https:\/\/doi.org\/10.1016\/j.exphem.2015.08.009.","journal-title":"Exp Hematol"},{"key":"4277_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/1471-2407-6-265","volume":"6","author":"L Markasz","year":"2006","unstructured":"Markasz L, Stuber G, Flaberg E, et al. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer. 2006;6:265. https:\/\/doi.org\/10.1186\/1471-2407-6-265.","journal-title":"BMC Cancer"},{"key":"4277_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/1471-2407-11-441","volume":"11","author":"R Otv\u00f6s","year":"2011","unstructured":"Otv\u00f6s R, Skribek H, Kis LL, et al. Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. BMC Cancer. 2011;11:441. https:\/\/doi.org\/10.1186\/1471-2407-11-441.","journal-title":"BMC Cancer"},{"key":"4277_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.exphem.2010.09.001","volume":"38","author":"H Skribek","year":"2010","unstructured":"Skribek H, Otvos R, Flaberg E, et al. Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol. 2010;38:1219\u201330. https:\/\/doi.org\/10.1016\/j.exphem.2010.09.001.","journal-title":"Exp Hematol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04277-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04277-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04277-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T01:02:13Z","timestamp":1703379733000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04277-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,24]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4277"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04277-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2023,12,24]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institution does not require ethical approval for reporting individual cases or case series.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"All authors claim no competing interests related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"529"}}